Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma

Emerging Infectious Diseases

Volumn 15, Issue 7, 2009, Pages 1088-1090

  Hong, Kevin Cyrus ^a   Schachter, Julius ^a   Moncada, Jeanne ^a   Zhou, Zhaoxia ^a   House, Jenafir ^a   Lietman, Thomas M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; DOXYCYCLINE; MACROLIDE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CHLAMYDIA TRACHOMATIS; DRUG DISTRIBUTION; DRUG SENSITIVITY; ENDEMIC DISEASE; ETHIOPIA; HUMAN; TRACHOMA;

ADMINISTRATION, TOPICAL; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; CHLAMYDIA TRACHOMATIS; CYCLOHEXIMIDE; DRUG RESISTANCE, MICROBIAL; ETHIOPIA; EYE DISEASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE;

EID: 67650680607     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1507.081563     Document Type: Article

References (12)

1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844-51.
2. Schachter J, West SK, Mabey D, Dawson CR, Bobo L, Bailey R, et al. Azithromycin in control of trachoma. Lancet. 1999;354:630-5. DOI: 10.1016/S0140-6736(98)12387-5
3. Fry AM, Jha HC, Lietman TM, Chaudhary JS, Bhatta RC, Elliott J, et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis. 2002;35:395-402. DOI: 10.1086/341414
4. Solomon AW, Mohammed Z, Massae PA, Shao JF, Foster A, Mabey DC, et al. Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrob Agents Chemother. 2005;49:4804-6. DOI: 10.1128/ AAC.49.11.4804-4806.2005
5. Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, House J, et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA. 2006;295:1142-6. DOI: 10.1001/jama.295.10.1142
6. Leach AJ, Shelby-James TM, Mayo M, Gratten M, Laming AC, Currie BJ, et al. A prospective study of the impact of communitybased azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis. 1997;24:356-62.
7. Lakew T, House J, Hong KC, Yi E, Alemayehu W, Melese M, et al. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Negl Trop Dis. 2009;3:e376.
8. Ripa KT, Mardh PA. Cultivation of Chlamydia trachomatis in cycloheximide-treated McCoy cells. J Clin Microbiol. 1977;6:328-31.
9. Bain DL, Lietman TM, Rasmussen S, Kalman S, Fan J, Lammel C, et al. Chlamydial genovar distribution after communitywide antibiotic treatment. J Infect Dis. 2001;184:1581-8. DOI: 10.1086/324661
10. Agacfidan A, Moncada J, Schachter J. In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 1993;37:1746-8.
11. Binet R, Maurelli AT. Fitness cost due to mutations in the 16S rRNA associated with spectinomycin resistance in Chlamydia psittaci 6BC. Antimicrob Agents Chemother. 2005;49:4455-64. DOI: 10.1128/AAC.49.11.4455-4464. 2005
12. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother. 2003;47:636-42. DOI: 10.1128/ AAC.47.2.636-642.2003